Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

60.44 +3.36 (+5.89%)

Streaming Delayed Price Updated: 12:47 PM EDT, Aug 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

36 37 Next >

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements ↗

February 01, 2024

Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.

Via InvestorPlace

Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock ↗

January 31, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added.

Via Benzinga

History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. ↗

January 30, 2024

Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.

Via The Motley Fool

Topics Stocks

Is CRISPR Therapeutics a Buy in the New Bull Market? ↗

January 30, 2024

CRISPR Therapeutics is a specialist in the hot technology of gene editing.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week ↗

January 28, 2024

Wood added to her existing positions in these three exciting companies.

Via The Motley Fool

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today ↗

January 22, 2024

Via Benzinga

Could CRISPR Therapeutics Stock Help You Become a Millionaire? ↗

January 22, 2024

CRISPR Therapeutics shares have soared 39% over the past three months.

Via The Motley Fool

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January ↗

January 25, 2024

These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.

Via InvestorPlace

These 5 growth stocks are now in buy ranges

January 25, 2024

Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs.

Via MarketBeat

Topics ETFs

Where Will CRISPR Therapeutics Be in 5 Years? ↗

January 24, 2024

The company could maintain the momentum it gained last year.

Via The Motley Fool

1 Setback and 1 Opportunity for CRISPR Therapeutics Stock ↗

January 23, 2024

Despite A bump in the road, the biotech's future looks sunny.

Via The Motley Fool

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today ↗

January 22, 2024

Has investing in Vertex been a better option than just putting your money in the S&P 500?

Via The Motley Fool

Topics Stocks

Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks ↗

January 22, 2024

The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase.

Via Investor's Business Daily

Topics ETFs

Could Editas Medicine Become the Next CRISPR Therapeutics? ↗

January 21, 2024

Via The Motley Fool

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics ↗

January 21, 2024

Both companies are going to continue doing high-impact science in 2024.

Via The Motley Fool

3 High-Flying Stocks That Could Soar Even More in 2024 ↗

January 20, 2024

These big winners could keep the momentum going.

Via The Motley Fool

3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026 ↗

January 18, 2024

Discover the trailblazing strategies of three tech stocks that are reshaping industries through innovation, adaptability and revenue surges.

Via InvestorPlace

Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares ↗

January 17, 2024

Via Benzinga

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule ↗

January 17, 2024

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...

Via Benzinga

Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units ↗

January 16, 2024

On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.

Via Benzinga

Topics ETFs

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock ↗

January 16, 2024

Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering.

Via Investor's Business Daily

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge ↗

January 16, 2024

These risky stocks can deliver big returns for investors.

Via The Motley Fool

Here's Why CRISPR Therapeutics Stock Rose 54% Last Year ↗

January 15, 2024

Key regulatory developments sent this biotech stock higher.

Via The Motley Fool

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

Down 88%, Could Editas Medicine Be a Good Investment Now? ↗

January 15, 2024

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

Via The Motley Fool

What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024? ↗

January 14, 2024

An acquisition could be both a blessing and a curse for long-term investors.

Via The Motley Fool

7 Healthcare Stocks Taking Medicine to the Next Level ↗

January 14, 2024

With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider.

Via InvestorPlace

My 3 Highest-Conviction Growth Stocks to Buy in 2024 ↗

January 14, 2024

Simply put, these stocks inspire confidence.

Via The Motley Fool

My 5 Top Growth Stocks to Buy Hand Over Fist for 2024 ↗

January 14, 2024

2024 could be a year of growth.

Via The Motley Fool

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.